About
Over the last 8 years, CCMI have successfully received regulatory approval to manufacture and release cellular materials for administration to patients undergoing Clinical Trials, namely, the treatment of critical limb ischemia, osteoarthritis, kidney disease and prevention of corneal rejection, after transplant. CCMI continue to provide specialised research, manufacturing and advisory services to clinical, academic, and industry partners for the pre-clinical and clinical development of advanced therapies. CCMI are a GMP compliant facility and are subject to ongoing HPRA routine inspections.
Andrew Finnerty
General ManagerMedicine 0035391494159
andrew.finnerty@nuigalway.ie
Website
View WebsiteAddress
Orbsen Building
University Road
NUIG
H91 TK33
Galway
Ireland
andrew.finnerty@nuigalway.ie
Areas of Expertise
- Analytics
- Cell therapy (Allogeneic)
- Cell Therapy (Autologous)
- Clinical
- Data Analysis
- Delivery
- Discovery
- Gene Therapy (non-viral)
- Manufacturing sciences
- Microscopy/Imaging
- Process Development
- Regulatory
- Supply chain
- Training
